Similarly, some studies have demonstrated that the numbers of PD-L1+ TAMs or PD-L1+ monocytes are associated with tumor progression and inversely associated with patient prognosis in multiple cancer types [181,182,183], whereas others studies have demonstrated that baseline numbers of PD-L1+ TAMs do not have predictive value for melanoma patients treated with anti-PD-1 immunotherapy [184]. This evidence concerns the gene CD274 and cancer.